Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-336

First 336 Last

Share
Profile

Follow
Napolian

551 Posts.

44

17/09/20

16:52

Post #: 47425987
Share

Originally posted by RLGphd: ↑

hey OvF,

sure I can try to explain more clearly, and yes I was on the call. What I believed they said on the call was that there was no statistical difference between placebo and drug in the lower albuminuria group - this is not to say that placebo correction was not positive across this whole subgroup. And it must be positive in order for these numbers reported to be possible. Keep in mind that only one arm should experience a legacy effect while the other should not as it starts with placebo so the net of the two arms should somewhat cancel each other out... but it does not come close for the low albuminuria subgroup.

so:
26 patients with an average reduction of 18%
14 patients with an average of x
40 total patients with an average reduction of 2%

14 patients would therefore have an average albuminuria increase of >25% in order for this 40 patient cohort to have an overall reduction of 2%

As mentioned before, without seeing exactly which patients are in which groups it’s not conclusive, but it is concerning that this is how the math has to work out overall

a legacy effect would be pretty easy to detect (if strong) once graphing individual patient data in each arm, yet they only shared one select group with us and didn’t tell us which patients were in which arm (and left out a point) even though they would definitely have done this for each patient - there’s only 40 patients total and it’s very fast

i just feel data is being withheld which makes me think it’s very messy and therefore unlikely to give us clear answers of what’s happening which makes me not want to bet on the subanalysis solving all our problems

Expand

The numbers in your post are placebo-adjusted which is calculated as reduction under DMX200 minus reduction under placebo

"
26 patients with an average reduction of 18%
14 patients with an average of x
40 total patients with an average reduction of 2%
"

The 25% increase reflects placebo has better result than the drug. One possible reason is legacy effect.

DXB Price at posting: 24.0¢ Sentiment: None Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

VNL

Vinyl expands into UK and European markets with acquisition of Serenade platform

ALY

Alchemy signs farm-in agreement with Japanese government for development of WA's Karonie

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 292 more messages in this thread...

First 336 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 39.0¢		Change 0.005(1.30%)		Mkt cap ! $217.2M

Open	High	Low	Value	Volume
38.5¢	39.0¢	38.0¢	$309.4K	797.1K

Buyers (Bids)

No.	Vol.	Price($)
2	32534	39.0¢

Sellers (Offers)

Price($)	Vol.	No.
39.5¢	85811	6

View Market Depth

No.	Vol.	Price($)
2	32534	0.390
6	101719	0.385
9	126416	0.380
11	223431	0.375
12	227718	0.370

Price($)	Vol.	No.
0.395	85811	6
0.400	140183	6
0.405	106609	7
0.410	63377	5
0.415	46000	2

Last trade - 10.45am 30/09/2024 (20 minute delay)

DXB (ASX) Chart

Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-336

Vinyl expands into UK and European markets with acquisition of Serenade platform

Alchemy signs farm-in agreement with Japanese government for development of WA's Karonie

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-336

Top Stories

Vinyl expands into UK and European markets with acquisition of Serenade platform

Alchemy signs farm-in agreement with Japanese government for development of WA's Karonie

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News